Dr. Habtewold’s work sits at the cutting edge of genetic and microbe-based vector biocontrol strategies aimed at blocking pathogen transmission in malaria-endemic regions.
Recognized internationally as a pioneering diaspora scientist, Dr. Habtewold has been instrumental in bridging advanced genetic technologies and local African scientific capacity. He led the team that developed Africa’s first transgenic mosquito capable of blocking malaria parasite development—a landmark achievement published in Nature. His expertise in CRISPR/Cas9 gene editing has driven the creation of novel anti-Plasmodium molecules integrated into mosquito genomes, setting new standards for innovative malaria control.
Beyond the lab, Dr. Habtewold champions capacity building and sustainable scientific development across Africa. He has played a central role in establishing high-security containment facilities, transferring gene-drive technology to regional institutions, and mentoring the next generation of African scientists. His commitment extends to fostering inclusive, collaborative research environments that empower local communities and institutions to lead malaria elimination efforts.
Featured as a leading example of how diaspora scientists supercharge Africa’s health innovation, Dr. Habtewold continues to influence global health through groundbreaking research, strategic partnerships, and dedicated advocacy for equitable scientific advancement on the continent.